H PGX - Thrombo StripAssay®The easy way to optimize coumarin anticoagulant therapy using established innovations in diagnostics PGX-Thrombo Assay. Key to efficient therapy. Stroke, myocardial infarction and venous thromboembolism are commonly treated and prevented by oral anticoagulants. Vitamin K antagonists (coumarins) are highly effective for that purpose. However, their narrow therapeutic range in combination with a wide variability in dose response poses a considerable risk to patients. Consequences of an inappropriate coumarin dose include life-threatening bleeding (overdose) or lack of therapeutic effect (insufficient dose). Hence, an individualized anticoagulation treatment is of paramount importance for the safety and health of patients. Coumarin derivatives inhibit the enzyme vitamin K epoxide reductase. Gene variants coding for its subunit 1 (VKORC1) affect the sensitivity to coumarins. Moreover, variants in the metabolizing cytochrome P450 isozyme CYP2C9 influence the coumarin turnover and thus the therapeutic effect of the drug. The PGX-Thrombo StripAssay® offers an easy way to identify the most relevant genetic variations influencing coumarin anticoagulation therapy.

The ViennaLab PGX-Thrombo StripAssay® meets customer requirements Requirement ViennaLab’s offer Three simple steps. 6 h. Done. Probes for variants and controls combined on one teststrip. Automated or manual processing. Incubator.Thermocycler. Shaker. That is all you need. Software for interpretation of results is optional. The ViennaLab PGX-Thrombo StripAssay® combines all these requirements. The ViennaLab PGX-Thrombo StripAssay® • is based on reverse-hybridization of biotinylated PCR products • combines probes for variants and controls in a parallel array of allele-specific oligonucleotides...